-
FDA Approves Subcutaneous Administration Of Takeda's Entyvio For Crohn's Disease
19 Apr 2024 02:16 GMT
… the U.S. Food and Drug Administration has approved Entyvio (vedolizumab … approved by FDA in September 2023 for the maintenance treatment of adults … with moderately to severely active ulcerative colitis (UC …
-
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
18 Apr 2024 23:08 GMT
… U.S. Food and Drug Administration (FDA) has approved ENTYVIO® … , giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended … who develop a severe infection while on treatment with … or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) …
-
Phase 3 Upadacitinib Study Achieves Positive Results for the Treatment of Giant Cell Arteritis
18 Apr 2024 15:39 GMT
… inhibitor, is used to treat a number of autoimmune conditions … moderate to severe ulcerative colitis, and moderate to severe … -mediated diseases by developing new treatments where significant medical … efficacy of continuing the drug compared with withdrawing …
-
Palisade Bio completes its analysis evaluating ex─vivo bioactivation of PALI─2108 for patients affected by ulcerative colitis
18 Apr 2024 11:06 GMT
… a biopharmaceutical company focused on developing and advancing novel therapeutics for … as a targeted treatment for moderate-to-severe ulcerative colitis," said … managing ulcerative colitis."
Palisade Bio continues advancing ongoing development of …
-
Louise Thompson joins her mother Karen as Zara McDermott launches her new clothing brand - after revealing she uses a stoma bag following battle with ulcerative colitis
17 Apr 2024 22:54 GMT
… of suffering from ulcerative colitis following a diagnosis in … autoimmune disease lupus.
Ulcerative colitis is a chronic bowel condition … become inflamed and small ulcers develop on the colon' … The procedure can be part treatment for a number of illnesses …
-
FDA Approves Second Ustekinumab Biosimilar
17 Apr 2024 22:10 GMT
… Drug Administration (FDA) has approved the biosimilar ustekinumab-aekn (Selarsdi) for the treatment … Alvotech in partnership with Teva Pharmaceuticals.
Ustekinumab (Stelara) is a … treating moderate to severely active Crohn's disease and ulcerative colitis …
-
New GPR183 antagonist demonstrates improved safety and promising efficacy in murine colitis model
17 Apr 2024 18:57 GMT
Gastrointestinal
Scientists from Shanghai Jiao Tong University and affiliated organizations have discovered novel GPR183 antagonists as potential therapeutic candidates for the treatment of inflammatory bowel disease (IBD). With the aim of improving the …
-
A Combined Approach of BWT and SMI for Assessing Endoscopic Improvement in Ulcerative Colitis
17 Apr 2024 17:49 GMT
… endoscopic improvement in ulcerative colitis: external validation of … therapeutic goal in managing ulcerative colitis (UC). Intestinal ultrasound … index (SMI), was developed as the ratio of … days without alterations in treatment between examinations. IUS …
-
New Data on Infection Avoidance and Development of pH Neutral Ketamine, for Intravenous & Subcutaneous Use NASDAQ: NRXP
17 Apr 2024 14:57 GMT
… Primary Causes of Pseudomembranous Colitis due to C Difficile … Yeast Infections.
Received FDA Qualified Infectious Disease Product … Pharmaceuticals around the development and marketing of NRX-101 for the treatment … -101 as a drug to treat CNS disease, these …
-
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101
17 Apr 2024 14:27 GMT
… 101 as a drug to treat CNS disease, these … Executive Officer of NRx pharmaceuticals.
About D-Cycloserine … C. diff associated colitis doubles hospital mortality and … developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment …